ORPHA:370348
Peripheral primitive neuroectodermal tumor
Also known as: PPNET · Peripheral PNET · Peripheral neuroepithelioma
Publications
1,696
Trials
49
Interventional, condition-specific
Researchers
1,039
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, aggressive, malignant, neoplastic disease characterized by a usually ill-defined, solid, multilobulated mass, frequently having necrosis, located on any site of the body (except the central nervous system), composed of small, round, poorly differentiated cells, with or without Homer-Wright rosettes, showing varying degrees of neuroectodermal differentiation. Manifestations are variable depending on location, with osteolytic destruction being common when arising from bone.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018271
- UMLS:C0684337
- NCIT:C9341
Additional Mondo synonyms (8)
pPNET · peripheral PNET · peripheral neuroectodermal neoplasm · peripheral neuroectodermal tumor · peripheral neuroectodermal tumour · peripheral neuroepithelioma · peripheral primitive neuroectodermal neoplasm · peripheral primitive neuroectodermal tumor
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,696 matched papers (607 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
49 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,696
1,696 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,696 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
607 in the last 10 years · low confidence
Phrase hits: 1,696 · MeSH hits: 0
Who's working on it?
1,039
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01
- 02Li Z5 papers · 2025
Department of Biostatistics, University of Washington, Seattle, WA, USA.
Papers in Europe PMC - 03Liu Y5 papers · 2020
Department of Pathology, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin 300100, P.R. China.
Papers in Europe PMC - 04Liu X4 papers · 2025
Department of Medical imaging, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Papers in Europe PMC - 05Mehrotra A4 papers · 2018
Department of Neurosurgery, SGPGIMS, Lucknow, Uttar Pradesh, India.
Papers in Europe PMC - 06Sahu RN4 papers · 2019
Department of Neurosurgery, SGPGIMS, Lucknow, Uttar Pradesh, India.
Papers in Europe PMC - 07Wang Y4 papers · 2023
Department of Neurosurgery, Tongji Medical School, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Papers in Europe PMC - 08Allali N3 papers · 2026
Pediatric and Gynecology Radiology Department, Children's Hospital, University Mohammed V, Rabat, Morroco.
Papers in Europe PMC - 09Behari S3 papers · 2018
Department of Neurosurgery, SGPGIMS, Lucknow, Uttar Pradesh, India.
Papers in Europe PMC - 10Bhaisora KS3 papers · 2018
Department of Neurosurgery, SGPGIMS, Lucknow, Uttar Pradesh, India.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
49
interventional trials for this specific condition
49 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 47 trials are registered for primitive neuroectodermal tumor, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
49 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 97th percentile).
low confidence · 97th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
49 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06441331·RECRUITING·Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Conditions: Somatostatin Receptor Positive · NETs · Lymphoma · Solid Tumor·Matched via name phrase
- NCT04901702·RECRUITING·Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Conditions: Recurrent Solid Tumor · Recurrent Ewing Sarcoma · Recurrent Hepatoblastoma · Recurrent Malignant Germ Cell Tumor·Matched via name phrase
Broader category: primitive neuroectodermal tumor
47
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT02508038·RECRUITING·Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Conditions: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Hodgkin Lymphoma · Non-Hodgkin Lymphoma·Matched via name phrase
- NCT06638931·RECRUITING·Agnostic Therapy in Rare Solid Tumors
Conditions: Urachal Cancer · Parathyroid Carcinoma · Fibrolamellar Carcinoma · Angiosarcoma·Matched via name phrase
- NCT03911388·RECRUITING·HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Conditions: Neoplasms, Brain · Glioblastoma Multiforme · Glioblastoma of Cerebellum · Neoplasms·Matched via name phrase
- NCT04185038·RECRUITING·Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
Conditions: Central Nervous System Tumor · Diffuse Intrinsic Pontine Glioma · Diffuse Midline Glioma · Ependymoma·Matched via name phrase
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Peripheral primitive neuroectodermal tumor" OR "PPNET" OR "Peripheral PNET" OR "Peripheral neuroepithelioma" OR "peripheral neuroectodermal neoplasm" OR "peripheral neuroectodermal tumor" OR "peripheral neuroectodermal tumour" OR "peripheral primitive neuroectodermal neoplasm"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Peripheral primitive neuroectodermal tumor" OR "PPNET" OR "Peripheral PNET" OR "Peripheral neuroepithelioma" OR "peripheral neuroectodermal neoplasm" OR "peripheral neuroectodermal tumor" OR "peripheral neuroectodermal tumour" OR "peripheral primitive neuroectodermal neoplasm"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 49 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"primitive neuroectodermal tumor"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1696) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T14:56:44.289Z
